Dose Insider / Glossary / Off-label use

Off-label useWhen a GLP-1 is prescribed outside its approved uses

Updated November 20, 2026 路 3 min read 路 FDA page on unapproved use of approved drugs; Wegovy, Ozempic, Rybelsus, Zepbound, Mounjaro and Saxenda labels

Off-label use is the use of an FDA-approved drug in a way FDA has not approved. FDA counts three kinds: for a disease or condition the drug is not approved to treat, in a different form than the approved one, or at a different dose.

3Wegovy injection, approved uses on each label
Approved uses on each labelNumber of indications, FDA labels 2026Wegovy injection3Ozempic injection3Rybelsus or Ozempic tablets2Zepbound2Mounjaro1Saxenda1Approved uses on each labelNumber of indications, FDA labels 2026Wegovy injection3Ozempic injection3Rybelsus or Ozempic tablets2Zepbound2Mounjaro1Saxenda1

Anything outside these uses is off-label.

On this page

Once a drug is approved, health care providers generally may prescribe it for an unapproved use when they judge it medically appropriate, but FDA has not determined that the drug is safe and effective for that use.1 A familiar GLP-1 example is Ozempic or Mounjaro prescribed for weight loss in someone without diabetes.

What approval covers

Before approval, the company must submit clinical data and show that the drug is safe and effective for its intended uses. FDA says "safe" does not mean free of side effects: it means the benefits for that use outweigh the potential risks. An approved use comes with labeling that lists the conditions the drug treats, how to use it for them, its risks, and what providers should discuss with patients. Some drugs also have Medication Guides, Patient Package Inserts and Instructions for Use written for patients.1 For an off-label use, FDA has made no such determination.

What each GLP-1 label covers

These are the approved uses as the first section of each label lists them in 2026:

Read against this list, Ozempic, Rybelsus and Mounjaro for weight loss alone are off-label, while Wegovy, Zepbound and Saxenda are approved for it. Semaglutide and tirzepatide are each sold under more than one brand name with different labels: the weight-loss brands carry the weight indication, and the diabetes brands do not.

Doses and forms count too

FDA's definition goes beyond the condition. A drug given in a different form, such as a liquid instead of an approved capsule, or at a different dose from the label, is also an unapproved use.1 The labels set out the approved doses and the steps between them, and a schedule outside them falls in the same category.

Why providers prescribe off-label

FDA gives two common reasons. There may be no approved drug for the condition, or a person may have tried all the approved treatments without benefit. In cases like these, the patient and the provider may discuss using an approved drug for an unapproved use.1

Questions FDA suggests asking

Adapted from FDA, understanding unapproved use of approved drugs.1

Sources

  1. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs "off label". Content current as of February 5, 2018, read November 20, 2026. fda.gov
  2. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; section 1. dailymed.nlm.nih.gov
  3. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 5.6 and 14.3. accessdata.fda.gov
  4. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information. Novo Nordisk; DailyMed, version 14, published August 19, 2026; section 1. dailymed.nlm.nih.gov
  5. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
  6. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 8.3, 11, 12 and 14. accessdata.fda.gov
  7. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 22, published June 15, 2026; section 1. dailymed.nlm.nih.gov

Related analyses

Log which brand and use your prescription is for, so insurance questions have an answer.

Open Dose Insider